Financial Health Snapshot
What does ResMed’s latest financial snapshot show?
Strong. ResMed’s best sign is strong cash generation alongside a 622% GAAP gross margin in Q3 2026. The main concern is post-acquisition liquidity and balance-sheet clarity after Noctrix closed after the quarter-end.
For the latest verified period, Q3 2026 and 2026-03-31, the verdict combines growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. That makes ResMed a useful case for studying financial health, especially alongside Mission Statement, Vision, & Core Values (2026) of ResMed Inc. (RMD).
Free Cash Flow deserves the first deeper look because it best shows whether ResMed can fund growth, dividends, and acquisition-related needs without straining liquidity.
Revenue and earnings quality
Is ResMed’s revenue growth producing quality earnings?
Strong. Revenue growth is being confirmed by higher net income and diluted EPS across comparable quarters, which points to real earnings conversion rather than one-off sales expansion.
ResMed’s growth looks more durable because revenue is rising across comparable periods while earnings are also improving. Investors compare revenue durability with operating income, net income, and EPS to see whether sales turn into actual profit, not just a larger top line. The link to Exploring ResMed Inc. (RMD) Investor Profile: Who's Buying and Why? is strongest when growth and per-share earnings move together.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $143B, 11% year-over-year, 2026-03-31 | $142B, 2025-12-31 | Organic growth; source split not supplied | Repeatable if demand stays broad and not dependent on one item |
| Operating Income | Not supplied | Not supplied | Unavailable in the provided data | Operating leverage cannot be tested here |
| Net Income | $39,873M, 2026-03-31 | $39,259M, 2025-12-31 | Higher profit alongside higher revenue | Final earnings support the top-line trend |
| Diluted EPS | $271, 2026-03-31 | $268, 2025-12-31 | Per-share growth improved | Shareholders saw earnings growth, not just business growth |
How durable is ResMed’s revenue growth?
The strongest signal is recurring sleep-therapy demand across devices, masks, and software. The biggest visibility limit is that customer concentration, pricing, and volume splits were not supplied, so the durability test is still partly qualitative.
- Demand Quality: Masks, connected devices, and software suggest recurring use, but exact retention or subscription rates were not supplied.
- Pricing and Volume: Price and volume were not separately supplied, so the revenue mix cannot be broken down cleanly.
- Diversification: Mix is split across Devices 51%, Masks and Other 37%, and Residential Care Software (RCS) 12% as of March 31, 2026.
That mix, plus 36M patient enrollments in AirView and 34M cloud-connected devices worldwide, points to scale and visibility before profitability and cash conversion.
Margins and Cash Quality
Are ResMed Inc.'s profits supported by cash flow?
ResMed Inc. shows strong gross margin performance and steady profit growth, while operating cash flow also improved, which supports earnings quality. Free cash flow cannot be fully confirmed here because capex dollars were not supplied, so cash conversion looks good but not complete.
Gross margin stayed in the low-60% range, while net income and operating income both moved higher across the supplied periods. That points to solid pricing and product mix, but reported earnings still need cash flow support. Operating cash flow improved, yet free cash flow quality depends on capital spending and working-capital movement.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | 62.2% in Q3 2026 | 62.3% in Q2 2026 | Reconfirmed FY 2026 gross margin guidance of 62%–63% supports stable product economics. | Product economics remain strong and consistent. |
| Operating Margin | Not supplied | Not supplied | Operating income rose from $49.760M at 2025-12-31 to $49.981M at 2026-03-31, but verified margin ratios were not provided. | Scale appears to support efficiency, but the exact margin trend is unavailable. |
| Net Margin | Not supplied | Not supplied | Net income increased from $39.259M at 2025-12-31 to $39.873M at 2026-03-31, but verified margin ratios were not provided. | Final profitability looks healthy, but the margin ratio cannot be confirmed. |
| Operating Cash Flow | $554M in Q3 2026 | $457M in Q1 2026 | Operating cash flow growth was reported at 6310% at 2026-03-31, showing a strong cash rebound. | Accounting earnings are being converted into operating cash. |
| Free Cash Flow | Unavailable; capex dollars not supplied | Unavailable; capex dollars not supplied | Capital expenditure was not provided, so free cash flow cannot be verified from the supplied data. | Reinvestment burden and financing capacity cannot be fully assessed. |
What most affects ResMed Inc.'s cash conversion?
The biggest verified driver is stronger operating cash flow, helped by solid margins and higher earnings, but free cash conversion still depends on capex and working-capital details that were not supplied.
- Main Driver: Higher operating income and gross margin look structural; the cash conversion boost may also reflect temporary working-capital timing.
- Evidence Gap: Capex dollars and working-capital detail are missing, so free cash flow quality cannot be fully tested.
- Metric to Monitor: Follow operating cash flow, capex, and FY 2026 gross margin guidance.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments.
For deeper academic or investment research, a DCF valuation model or company financial analysis template can help connect ResMed Inc.'s strategy with revenue, margins, cash flow, and valuation assumptions. You can also review Exploring ResMed Inc. (RMD) Investor Profile: Who's Buying and Why? for a broader investor view.
Liquidity Capacity
Does ResMed Inc. have enough liquidity and balance sheet capacity to fund operations, dividends, buybacks, and acquisitions?
ResMed Inc. looks Strong overall, with a net cash position and ample current assets. The main protection is $166B in cash and cash equivalents, while the main concern is funding and balance-sheet impact after the $340M Noctrix deal and the lack of disclosed maturity and covenant detail.
Cash alone is not the full test. For ResMed Inc., the key question is whether working capital, asset quality, debt service, solvency, liquidity, and refinancing all hold together. The latest 2026-03-31 balance sheet shows a solid cushion, but post-quarter acquisition effects still need follow-up.
If you’re using this topic for a paper or case study, Mission Statement, Vision, & Core Values (2026) of ResMed Inc. (RMD) can help connect balance-sheet strength to strategy and capital allocation.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Cash And Cash Equivalents: $166B; Short Term Investments: $548M; Total Current Assets: $406B; Total Current Liabilities: $135B; Net Receivables: $99884M; Inventory: $91188M | Strong | Near-term obligations appear covered without forcing an immediate pullback in investment. |
| Total and Net Debt | Short Term Debt: $28916M; Long Term Debt: $40417M; Capital Lease Obligations: $14984M; Total Debt: $84317M; Net Debt: -$81734M | Strong | Leverage is low relative to liquidity, so financial flexibility is still intact. |
| Debt Service and Refinancing | Debt maturities, interest expense, covenants, and credit-access detail were not supplied; the main verified support is a net cash position at 2026-03-31. | Mixed | ResMed Inc. likely has room to pay and refinance, but the missing maturity profile leaves some uncertainty. |
| Asset Quality | Total Assets: $878B; Property Plant Equipment Net: $72857M; Goodwill: $304B; Intangible Assets: $42519M; Goodwill And Intangible Assets: $347B | Mixed | Acquisition-linked assets are large, so collection risk is modest but impairment risk should be watched after Noctrix. |
| Liabilities and Equity | Total Liabilities: $229B; Total Stockholders Equity: $649B | Strong | The equity base is large enough to absorb stress and support ongoing capital use. |
Which balance-sheet risk matters most for ResMed Inc.?
The biggest issue is post-quarter acquisition funding and balance-sheet follow-through, not current solvency. The Noctrix transaction closed after the 2026-03-31 balance sheet, so updated cash, debt, and goodwill figures matter most.
- Current Exposure: Short Term Debt of $28916M plus total liabilities of $229B need monitoring after the Noctrix close.
- Protection: Net Debt of -$81734M and Cash And Cash Equivalents of $166B provide the main buffer.
- Warning Signal: Watch for lower cash, higher debt, or goodwill growth if acquisition spending continues.
Capital Efficiency
Is ResMed reinvesting cash without weakening shareholder returns?
Mixed. ResMed appears to be funding reinvestment with internal cash, but shareholder returns and post-acquisition funding pressure are not fully verifiable from the supplied data, so cash sufficiency looks adequate but not proven strong.
Return quality has to be read alongside leverage, asset intensity, capital expenditure, working capital, and outside funding needs. ResMed Inc. (RMD): History, Ownership, Mission, How It Works & Makes Money helps frame how this capital allocation mix fits the business model.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable in the supplied data. | Operating margin and capital efficiency cannot be verified directly from the prompt. | Investors cannot confirm whether invested capital is creating operating value from the available figures. |
| ROE and ROA | Unavailable in the supplied data. | Leverage and asset-intensity effects cannot be separated without the missing return metrics. | Shareholder return quality and asset efficiency remain unproven, so leverage should not be treated as automatic strength. |
| Maintenance and Growth Investment | $400M FY 2025 R&D investment, about 8% of annual revenue; FY 2026 Outlook R&D Expenses: 6%–7% of revenue; product work includes AirTouch F30i Comfort, FDA clearance for Smart Comfort, limited US beta rollout for myAir app users with AirSense 11 devices, and an ŌURA partnership. | The mix supports active reinvestment, but the maintenance-versus-growth split is not fully disclosed. | ResMed appears to be funding product and technology growth, which can support future earnings if returns exceed the cost of that spending. |
| Internal Funding Capacity | Quarterly Cash Dividend: $0.60 per share declared April 30, 2026, January 29, 2026, and October 30, 2025; Q1 2026 buyback of 523K shares for $150M; Outstanding Common Stock: 14506M shares; Treasury Shares: 4583M shares at March 31, 2026. | Ongoing dividends and buybacks suggest internal funding, but the completed Noctrix Health acquisition for $340M leaves post-deal liquidity detail incomplete. | Cash generation appears to support reinvestment and capital returns, though external funding risk cannot be ruled out from the supplied data alone. |
Are ResMed's returns on capital sustainable while it keeps reinvesting cash?
Probably, but not fully proven. The strongest durability signal is continued R&D-backed product momentum, while the main weakening risk is higher integration or liquidity pressure after the Noctrix Health acquisition.
- Operating Source: R&D-led launches and AI, IoT, and materials science spending support pricing and mix.
- Funding Requirement: The largest verified need is ongoing R&D plus the $340M Noctrix Health acquisition.
- Durability Test: Returns weaken if dividend, buyback, or acquisition spending rises while cash flow or margin coverage tightens.
Mixed resilience
How resilient is ResMed, and which warning signs matter most?
ResMed’s resilience is Mixed. The main buffer is strong cash generation and stable margins, with Q3 2026 GAAP gross margin at 62% and operating cash flow at $554M. The most important verified warning sign is the CFO transition, because execution and reporting consistency matter during leadership change.
ResMed can still protect liquidity and essential investment if pressure rises because core margins are solid and FY 2026 gross margin guidance stayed at 62%–63%. The question is whether cash discipline holds through leadership change, Noctrix integration, restructuring charges, and foreign exchange swings. The mission context on Mission Statement, Vision, & Core Values (2026) of ResMed Inc. (RMD) helps frame that test.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Lower operating leverage would reduce earnings, cash flow, and debt capacity if gross margin weakens or revenue slows. | Recurring demand and reconfirmed FY 2026 gross margin guidance at 62%–63% support resilience. | Watch for declining revenue, gross margin, or operating cash flow. |
| Working-Capital or Investment Pressure | Receivables growth, inventory shifts, capex, R&D, or acquisition spending can absorb cash and limit flexibility. | Operating cash flow of $554M shows internal funding strength, but the balance sheet must absorb new commitments. | Monitor operating cash flow, receivables growth, inventory growth, and acquisition-related expense or goodwill build. |
| Interest or Refinancing Pressure | Higher interest expense or tighter financing would reduce free cash flow and squeeze future investment capacity. | Cash generation helps, but debt-maturity detail was not provided, so liquidity coverage is not fully visible. | Watch interest expense, refinancing needs, and any liquidity deterioration. |
Which financial warning signs should investors monitor at ResMed?
The top signals are CFO transition execution, Noctrix integration costs, and any margin or cash-flow slip. The first two are future-risk watch items; a drop in gross margin or operating cash flow would be confirmed deterioration.
CFO Transition Discipline
Brett Sandercock retired effective May 4, 2026 and remains Special Advisor through December 31, 2027, while Aaron Bloomer became CFO the same day. The overlap helps, but investors should watch guidance consistency, reporting tone, and cash discipline.
Noctrix Integration and Capital Allocation
The $340M Noctrix deal closed on June 01, 2026, after the latest balance sheet. That raises exposure to cash use, debt, goodwill, intangible assets, and integration charges; monitor operating expenses and acquisition-related costs.
FX and Restructuring Pressure
ResMed had $132B of outstanding foreign currency hedging contracts at March 31, 2026, and recorded $6M of restructuring charges on April 30, 2026. Hedging helps, but investors should still watch revenue translation, gross margin, and other comprehensive income effects.
Financial Health Scorecard
What does ResMed’s financial health mean for investors?
ResMed earns a Strong overall rating. The biggest strength is high gross margin and strong operating cash flow; the main weakness is the limited evidence gap around post-acquisition liquidity and the debt maturity profile. The most important financial condition is whether cash generation stays durable after Noctrix and restructuring.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | Q3 2026 revenue was $143B, up 11% year-over-year, with net income of $39873M and diluted EPS of $271, showing solid conversion into per-share earnings. |
| Profitability and Cash | Strong | GAAP gross margin was 62.2%, operating income was $49981M, and operating cash flow was $554M, which supports durable profit quality and cash generation. |
| Balance Sheet and Liquidity | Strong | Cash and cash equivalents were $166B versus total debt of $84317M, leaving -$81734M net debt and a strong liquidity cushion, though maturity detail is not provided. |
| Capital Efficiency | Mixed | R&D, dividends, buybacks, and M&A are active, but ROIC, ROE, ROA, capex dollars, and dividend coverage are not supplied, so capital returns are harder to judge. |
| Financial Resilience | Mixed | Margins and cash are strong, but CFO transition, $6M restructuring charges, $132B notional FX hedging exposure, and Noctrix integration need close monitoring. |
- What Supports the Thesis: Strong gross margin, positive operating cash flow, and negative net debt point to a cash-generating healthcare business with solid FY2026 earnings conversion.
- What Challenges the Thesis: Post-acquisition liquidity, debt timing, and integration risk remain less visible after Noctrix and restructuring.
- What to Monitor: Operating Cash Flow, Cash And Cash Equivalents, Gross Margin.
This scorecard matters because forecast quality, scenario analysis, and valuation sensitivity all depend on whether ResMed can keep converting growth into cash.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
Why is ResMed’s gross margin above 60%?
ResMed reported GAAP Gross Margin: 622% in Q3 2026 and reconfirmed FY 2026 Outlook for Gross Margin: 62%–63% The outline should connect this to product economics, mix, and operating execution, while avoiding unsupported claims about pricing or permanent margin expansion
How strong is ResMed’s operating cash generation?
Operating cash generation looks strong based on Operating Cash Flow: $554M in Q3 2026 and Operating Cash Flow Growth: 6310% at 2026-03-31 Investors should still verify capex and working-capital movements before making free cash flow conclusions
Does ResMed need external funding after Noctrix?
The provided data does not show a confirmed external funding need At 2026-03-31, ResMed had Cash And Cash Equivalents: $166B, Total Debt: $84317M, and Net Debt: -$81734M, but Noctrix closed after that balance sheet
What does ResMed’s FX hedging exposure mean?
ResMed had Notional Value: $132B of outstanding foreign currency hedging contracts as of March 31, 2026, mainly for Euro, Australian Dollar, and Singapore Dollar exposures This shows risk management activity, not full protection from currency effects
Are ResMed dividends supported by financial health?
ResMed declared a Quarterly Cash Dividend: $060 per share on April 30, 2026 and produced Operating Cash Flow: $554M in Q3 2026 Dividend coverage cannot be fully assessed here because free cash flow dollars and payout ratios are not supplied